Legislative Priorities

IowaBio member companies are some of the top innovators in the pharmaceutical development space. They provide invaluable impact on patient health and quality of life, and also provide critical animal health innovations to protect and enhance our food supply. Ensuring the treatments and innovations in these industries are affordable and accessible, and that the regulatory environment supports and encourages such innovation is as important as the innovation itself.

Patient Access and Affordability:

• IowaBio supports patient access and affordability legislation to ensure all amounts paid on behalf of a patient count towards their out-of-pocket costs, including co-pay accumulator prohibition legislation, and closing the essential health benefits loophole, so that payers and PBMs cannot circumvent the Affordable Care Act by deeming a medicine non-essential.
• IowaBio will closely monitor and evaluate any anticipated legislation or regulations regarding the federal 340B Program, drug pricing and transparency.
• IowaBio supports biomarker legislation to enable patient access to tailored treatment.
• IowaBio supports rare disease advisory council and non-medical switching/continuity of care legislation.

Public Health and Vaccines:

• IowaBio supports strong, science-backed immunization policies and opposes additional exceptions to Iowa’s law requiring childhood vaccinations. IowaBio will strive to be a resource to the legislature and other stakeholders on Industry’s efforts to research and develop innovative vaccines and treatments for COVID-19 and other vaccine-preventable diseases, including vaccine dissemination, effectiveness, and safety.

Animal Health:

• IowaBio supports the development of cutting-edge animal vaccines and opposes efforts to hinder development or ban access to these critical agricultural tools.